# PT-141 (Bremelanotide)

> PT-141, known by the generic name bremelanotide, is a synthetic peptide derived from the melanocortin hormone alpha-MSH. It is studied primarily for its effects on sexual desire and arousal, acting through the central nervous system rather than the vascular pathways targeted by other therapies for sexual dysfunction. Bremelanotide received FDA approval under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Outside of its approved indication, it has drawn research and off-label interest for use in men, though this application is less established. As with any compound affecting hormonal and neurological pathways, individual response varies and effects are not guaranteed.

- URL: https://www.lifeconverted.com/peptides/pt-141
- Also known as: Bremelanotide
- Primary category: Sexual Health
- Effectiveness rank: #1 in Sexual Health
- Evidence level: Well studied
- Route: Subcutaneous
- Dose range: 500-1,750 mcg
- Dose tiers: low 500 mcg; moderate 1000 mcg; high 1750 mcg
- Half-life: Approximately 2 to 3 hours, based on published pharmacokinetic data.
- Timing: ~45 min before activity
- Cycle: Used on an as-needed basis rather than a continuous daily cycle on, No mandatory off period beyond spacing individual doses at least 24 hours apart off (Clinical labeling suggests limiting use to roughly 8 doses per month; consult a prescriber for guidance specific to individual health status.)
- Storage: Store unreconstituted lyophilized powder refrigerated at 2-8°C, protected from light. Follow reconstitution instructions precisely; use reconstituted solution within the timeframe specified by the supplier or prescribing information, keeping refrigerated between uses.

## Mechanism of action

Bremelanotide acts as a non-selective agonist at melanocortin receptors, with particular affinity for MC3R and MC4R subtypes in the hypothalamus. Activation of these receptors is believed to modulate dopaminergic pathways associated with sexual motivation and arousal. Unlike PDE5 inhibitors, its mechanism does not depend primarily on vascular blood flow, which is why it is studied for desire-based rather than purely physiological sexual dysfunction.

## Reported benefits

- Studied for supporting sexual desire and arousal in individuals with hypoactive sexual desire disorder
- Acts via central nervous system pathways rather than vascular mechanisms
- FDA-approved formulation (Vyleesi) available with established clinical trial data
- Effects reported to occur within a few hours of administration in clinical studies
- May be considered when vascular-targeted therapies are not appropriate, per a prescriber's guidance

## Reported side effects

- Nausea, reported as the most common effect in clinical trials
- Flushing and headache
- Transient increases in blood pressure and decreased heart rate
- Injection site reactions
- Hyperpigmentation of skin or gums with repeated use

## Common protocols

- Single as-needed subcutaneous dose taken several hours before anticipated activity
- Limited-frequency use pattern (not daily) consistent with approved labeling

## Stacking notes

Some discussions in research literature note potential interaction with medications affecting blood pressure or heart rate; combining with other melanocortin-pathway compounds is not well studied and should be approached cautiously.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer